Bing Wang

Bing Wang is the CEO of Clinical Pharmacology & Pharmacometrics at Amador Bioscience. Bing has over 20 years of experience in the pharmaceutical industry, specializing in clinical pharmacology and pharmacokinetics.

Wang began their career as a Scientist at Amgen in 1999, where they worked for four years before being promoted to Senior Scientist. In 2004, they left Amgen to join Abgenix as a Clinical Pharmacologist II. Bing spent two years at Abgenix before moving to AstraZeneca Pharmaceuticals as a Principal Scientist in 2006.

Wang spent a year at AstraZeneca before moving to MedImmune, where they spent 10 years in various roles, ultimately becoming a Fellow and Director of Clinical Pharmacology & Pharmacometrics. In April 2017, they left MedImmune to start their own consulting company, Lucid Clin Pharm Solutions, LLC, where they served as President and Principal Consultant for 10 months.

In February 2018, Wang joined Amador Bioscience as CEO of Clinical Pharmacology & Pharmacometrics.

Bing Wang received a certificate from the Center for Creative Leadership, a PhD from the University of Nebraska Medical Center, an MS from the University of Kansas, and a BS from the University of Science and Technology of China.

Some direct reports include Jayde Jin - Director of Statistical Programming, Jennifer Konwerski - Business Development Manager, and Huali Wu - Director, Pharmacometrics.